anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
268,330. Senftner &amp; Co., Ges., Dr., (Assignees of Senftner, G.). March 25, 1926, [Convention date]. Radio-active preparations.-In rendering water contained in bottles radio-active, the radio-active substance is contained in a flexible cage which is sufficiently resilient to allow insertion into or removal from a bottle through the neck, and prevent accidental removal therefrom or contact between the substance and the walls of the vessel. The radio-active material is enclosed in an insoluble envelope P, permeable to the emanations and carrying resilient arms F bent outwards at r. In a modification, the radio-active substances mav be contained in a mass of substance such as paraffin or compressed kieselguhr, the spring arms being secured to the mass. The Specification as open to inspection under Sect. 91 (3) (a) describes also a form shown in Fig. 2 (Cancelled) wherein the radio-active substance a is enclosed in a wire gauze envelope b of non-corrodible metal and this is enclosed in a wire cage c of similar material, the wires being forced out at the centre and the ends soldered to plates e. The dimensions of the centre are such that the cage can be forced through the neck of a bottle. The wires may be arranged in conical form or transversely to the axis of the container or spirally. This subject-matter does not appear in the Specification as accepted.
PURPOSE:An autiulcer having more improved activity with a small amount than ones on the market and low toxicity, comprising 2-(4-ethyl-1-piperazinyl)-4- phenylquinoline or its salt as an active ingredient. CONSTITUTION:An autiulcer comprising 2-(4-ethyl-1-piperazinyl)-4-phenylquinoline shown by the formula II or its salt as an active ingredient. The compound shown by the formula is well-known as an antidepressant, drug for Parkinson&#39;s, disease, etc., and found newly to have improved antiulcer action. The compound shown by the formula has improved inhibitory action of formation of ulcer and inhibitory action on secretion of acid in the stomach, and is useful as an antiulcer. Oral administration is preferable as administration form. A dose is 0.1- 6mg/kg/day, preferably 0.2-2mg/kg/day.
The present invention provides novel methods for classifying, diagnosing &#39;and/or treating a group of human and veterinary ailments involving endogenous opioid concentrations. Also provided is a novel use for an existing class of compounds, the opioids, to treat opiopathic ailments, particularly paresis/paralysis, pseudo-atrophy and/or opiopathic pain, and in the manufacture of pharmaceutical and veterinary formulations therefor. The invention also relates to neuropathic, polyneuropathy, neurologic and neurogenic ailments typically characterized by paresis/paralysis. These ailments can involve an abnormal concentration of one or more endogenous opioids, or the blockade, underexpression or overexpression of one or more opioid receptors. In that regard, the invention encompasses therapeutic uses, methods and compositions employing opiates and/or their receptors. In particular, the invention relates to certain laboratory testing methods, clinical testing methods, research and development methods, business methods, methods of treatment, novel therapeutic uses, and human and veterinary pharmaceutical dosage forms, dosing regimens and formulations, especially those pertaining to opiopathy (particularly hypo-opiopathy).
NEW MATERIAL:A 2-aminoimidazoline compound expressed by formula I (R&lt;1&gt; is H or lower alkyl; R&lt;2&gt; is H, lower alkyl or benzyl) and an acid addition salt thereof. EXAMPLE:2-(2,6-Dichlorophenyl-2-hydroxyiminoethyl)aminoimidazoline (2). USE:A preventing and treating agent for cardiac insufficiency or diseases in coronary arteries, and cardiac arrhythmia, hypotensive agent, anti-inflammatory agent and analgesic agent. PREPARATION:A hydroxytetrahydroimidazole derivative expressed by formula IIis reacted with hydroxylamine expressed by formula III or a mineral acid salt of an ether compound thereof preferably in an organic acid, e.g. acetic acid, to afford the aimed compound expressed by formula I . The compound expressed by formula II is obtained by reacting a halogenated acetaldehyde or halogenated acetone expressed by formula IV (R&lt;3&gt; is H or methyl; Hal is Cl, Br or I) with 2- (2,6-dichlorophenyl)aminoimidazoline (2) expressed by formula V.
FIELD: medical equipment.SUBSTANCE: group of inventions relates to medical equipment, specifically to a method for controlling an infusion pump by means of a controller, designed to control the pump and obtain data from a glucose sensor and a diabetes management system. Method comprises obtaining a series of measurements of glucose concentration in a patient. Glucose measurements were taken by a glucose sensor to measure glucose for each time interval from a series of indexed discrete time intervals. Glucose calibration measurement is then taken during the time interval from a series of indexed time intervals to obtain a calibration index. Further, it is determined whether glucose measurement was performed outside the time interval from the series of indexed time intervals to obtain an omission index. Tuning factor is then determined based on both the calibration index and omission index. Amount of insulin administered is then calculated by a controller with control, based on a predictive model. Predictive model uses: the plurality of glucose measurements to predict a trend of the glucose level from estimates of a metabolic state of the patient and the tuning factor so as to provide a calculated insulin amount to be delivered to the patient for each interval of the indexed time interval. System for treating diabetes comprises a glucometer for the occasional measurement of glucose in the patient&#39;s blood at time intervals and presentation of a similar occasional blood glucose level in the form of calibration indices for each time interval in the indexed time interval. System also comprises a glucometer for continuous measurement of glucose level in the patient&#39;s blood through discrete uniform time intervals and representations of glucose level for each interval in the form of glucose measurement data, in which any omission of glucose measurement through any time interval is stored as an omission index. System comprises an infusion pump for insulin to deliver insulin and a controller, connected to the pump and glycometers. Controller determines the tuning factor based on the calibration index obtained during occasional glucose measurements, and the omission index for the control predictive model. Controller determines the speed of delivery of insulin for each time interval in the indexed time interval from the control predictive model based on the required glucose level.EFFECT: technical result is the adjustment of the control predictive model based on two variables obtained during continuous glucose monitoring.7 cl, 4 dwg, 5 tbl
PROBLEM TO BE SOLVED: To obtain the subject new compound derivative useful as a medicine, etc., e.g. anticancer agent, immunosuppressant or anti-HIV agent by reacting a specific protected disaccharide derivative with a specific alcohol derivative containing an unsaturated long-chain aliphatic hydrocarbon group and deprotecting the reaction product. SOLUTION: This new β-digalactosylceramide derivative is represented by formula I (R&lt;2&gt; is pentadecanyl group, heptadecanyl group or 8heptadesenyl group) and useful as a medicine, etc., effective for indications, e.g. anticancer agents (anticancer agents or metastasis suppressants), immunosuppre&#39;ssants (for organ transplantation, etc.), anti-HIV agents, antitoxin action and Gauche disease. The compound is obtained by reacting a protected disaccharide active substance represented by formula H (R&lt;1&gt; is a protecting group of hydroxyl group; X is a halogen) with an alcohol derivative represented by the formula ROH [R is a group of formula III (R&lt;3&gt; is same kind as R&lt;2&gt; ) to afford a protected β- digalactosylceramide derivative represented by formula IV and then, deprotecting the derivative.
&lt;P&gt;PROBLEM TO BE SOLVED: To easily relate a medical image to be added to a site.  &lt;P&gt;SOLUTION: A first storage section 66 stores a first medical image, position information in the first medical image, and site information corresponding to the position information. A second storage section 68 stores a second medical image. A display section 50 displays the first medical image and the second medical image. A selection section 54 selects the second medical image to be related to the first medical image. A specification section 56 specifies the position to which the selected second medial image should be related, which is the position on the displayed first medical image. An extraction section 60 extracts site information related to the specified position on the basis of the specified position and the position information. A third storage section 70 stores the relation of the extracted part information to the selected second medical image.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
Opioid peptides or physiologically acceptable salts thereof are obtained by hydrolysing wheat protein eg. gluten with one or more acid proteases eg. pepsin, aspartic proteinases, and with one or more neutral proteases e.g. chymotrypsin, trypsin and/or alkaline proteases eg. cerin protease. Opioid peptides 50 obtained have been identified as:      Gly-Tyr-Tyr-Pro      Gly-Tyr-Tyr-Pro-Thr      Gly-Tyr-Tyr-Pro-Thr-Ser      Tyr-Pro-Ile-Ser-Leu      Tyr-Gly-Gly-Trp-Leu      Tyr-Gly-Gly-Trp They are useful as narcotics and analgesics, and may be produced synthetically. &lt;IMAGE&gt;
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method and an apparatus which can be suitably used for producing a fine particle dispersion liquid at high efficiency in a short time.  &lt;P&gt;SOLUTION: In a dissolution step, a poorly-soluble drug and a dispersion stabilizer are dissolved in a volatile organic solvent. In a fixing step, the organic solvent present in the solution prepared in the dissolution step is removed by evaporation and the residue 1 in the form of a pellet is prepared by removing the organic solvent, and the residue 1 is fixed on respective bottoms of a plurality of places in a container 30. In a water-pouring step, water 2 is poured into a respective plurality of recesses 31 in the container 30. In an irradiation step, the residue 1 fixed on respective bottoms of a plurality of recesses 31 in the container 30 is simultaneously or successively irradiated with a laser beam L emitted from a beam irradiation section 20, thereby pulverizing the residue 1 to fine particles. Accordingly, these fine particles are dispersed into the water 2 to produce a fine particle dispersion.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
Systems and methods are provided herein for treating a patient in cardiogenic shock. An intravascular heart pump system is inserted into vasculature of the patient. The heart pump system has a cannula, pump outlet, pump inlet, and rotor. The heart pump system is positioned within the patient such that the cannula extends across the patient&#39;s aortic valve, the pump inlet is located within the patient&#39;s left ventricle, and the pump outlet is located within the patient&#39;s aorta. Data related to time-varying parameters of the heart pump system is acquired from the heart pump system. A plurality of features are extracted from the data. A probability of survival of the patient is determined based on the plurality of features and using a prediction model. The heart pump system is operated to treat the patient.
The present invention relates to fengbao antitussive liquid, which is characterized in that the medicine is produced with the following raw materials in weight proportions: 8 to 12 proportions of honey, 0.5 to 1.5 proportions of royal jelly, 1 to 3 proportions of honeycomb and 6 to 10 proportions of propolis. The honeycomb is dissolved and filtered after 5 to 15 proportions of water is added, the honey, the royal jelly and the propolis are put into the dissolved and filtered liquid for mixing. Then the finished medicine can be obtained. The present invention has the remarkable advantages that: the &#39;fengbao antitussive liquid&#39; produced by adopting the method provided by the present invention can be used for curing a variety of coughs with simple method. The &#39;fengbao antitussive liquid&#39; is rapid in relieving a cough and good in effect without side effect. Patients suffer from no pain. The cost is low. The &#39;fengbao antitussive liquid&#39; is suitable for mass consumers.
PROBLEM TO BE SOLVED: To obtain the subject preparation capable of disinfecting and physically protecting cattle hooves and sustaining their effects by homogeneously mixing a spreading agent with a mixture containing in specified proportions two kinds of metal salts differing in ionization tendency from each other, i.e., a metal salt whose aqueous solution is alkaline, and the other metal salt having antimicrobial effect. SOLUTION: This preparation comprises (A) 20.0-60.0 wt.% of a sparingly water-soluble metal salt exhibiting alkalinity (pref. calcium carbonate, calcium oxide or the like), (B) 0.1-10.0 wt.% of at least one metal salt having antimicrobial effect (pref. salt(s) of silver, zinc and/or copper) and (C) 20.0-60.0 wt.% of a spreading agent (pref. based on a synthetic latex); wherein the component A is pref. &lt;=3 μm in particle size and &gt;=30 wt.% in metal atom content, the component B is pref. &gt;=30 wt.% in metal atom content, and the component C is preferably powder and soluble in water. This preparation thus obtained has adhesive force and settability to cattle hooves, exhibiting intended effect.
Formulations have been developed which assist individuals having an addiction such as smoking to reduce or quit engaging in the addictive behavior. Representative behaviors include smoking, excessive alcohol or food ingestion, drug addiction, and ingestion of caffeine or junk food providing quick &#39;highs&#39;. The formulations assist the smoker to become dissatisfied with smoking, until he or she willingly gives up the habit or at least cuts down on the number of cigarettes smoked per day as an initial step towards quitting in the future. The formulations can also be used in conjunction with other known formulations, such as nicotine gum or patch. The formulations contain hydrophilic polymers, for example, polyethylene glycol (PEG) alone or in combination or polyvinyl pyrrolidone (PVP) (also known as povidone or polyvidone alone or in combination.), sweeteners and/or flavorings, viscosity modifiers/binders, and pH or buffering agents.
PURPOSE:To obtain the titled composite, by dissolving a hardly water-soluble drug and a phospholipid in an organic solvent, distilling off the solvent to form a thin film of phospholipid containing the drug, treating the film with ultrasonic wave, centrifuging the treated product, and recovering the bottom precipitate. CONSTITUTION:A hardly water-soluble drug having a water-solubility of &lt;=0.1mg/ml (e.g. spadicomycin, anthramycin, fluorouracil, etc.) and a phospholipid (e.g. phosphatidylcholine, phosphatidylserine, soybean phospholipid, yolk phospholipid, etc.) are dissolved in an organic solvent such as chloroform. The amount of the hardly water-soluble drug is preferably 0.01-10pts.wt. per 1pt.wt. of the phospholipid. A phospholipid thin film containing the drug is formed by distilling off the solvent, the suspension of the thin film is treated with ultrasonic wave and centrifuged, and the obtained bottom precipitate is recovered to obtain the objective composite of the hardly water-soluble drug and the phospholipid. The activity of the drug increases several times - several tens times by the solubilization effect, and a unusually effective drug preparation can be prepared.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to solid frothed medicinal preparations containing active component and at least one thermoplastic polymer. Active component is taken among ibuprofen, ketoprofen, flurbiprofen, acetyl- -salicilyc acid, verapamil, paracetamol, nifedipin, caffeine, captopril and vitamins or mixture of two or some indicated active components. Thermoplastic polymer presents a homopolymer or copolymer of N-vinylpyrrolidone with Fickentscher&#39;s coefficient in the range from 10 to 30. Prepared frothed preparations are dissolved easily due to the presence of active component that is dispersed in polymeric matrix homogeneously providing rapid release of active component. EFFECT: improved properties of preparations. 2 ex
A steel cylinder open at both ends, has a ratio of internal dia. to length of 0.50-0.75; a volumetric mass of 2.0-3.5g per cubic centimeter; a series of grooves cut into its internal surface to a depth of 20-50% of its thickness; and is clad all over with a chemically resistant material. The cylinder is used to orally distribute a pharmaceutical substance into the first and second stomachs of ruminants under controlled conditions of release over the period of the animal&#39;s development. The cladding is a substance that does not activate the depolymerization of a copolymer obtd. from about 60-95wt. % of lactic acid and about 40-50wt. % of glycolic acid.
PURPOSE:To obtain the titled ointment useful for the remedy of dermatosis caused by trichophyton, e.g. athlete&#39;s foot, etc., by adding glacial acetic acid to a base solution containing oxalic acid and broic acid. CONSTITUTION:Small amounts of oxalic acid and boric acid are added to a mixture of sterile water and ethyl alcohol, and the mixture is heated at 90 deg.C to obtain a base solution. The solution is cooled slowly to 55 deg.C, added with glacial acetic acid, and stirred to obtain the objective ointment. Oxalic acid is known to have activity to athlete&#39;s foot. Boric acid is added to prevent the damage of the diseased part by the ultrafine powder of oxalic acid, and glacial acetic acid is used to remove the degraded waste horny layer produced by the toxin of trychophyton. The mycelia surrounding the diseased part is floated by the metabolism of the horny layer in the course of treatment, and changes its color first from pale pink color, gradually to pale brown, and finally to the freckle color before falling off from the skin to leave the skin with healthy appearance.
PURPOSE: To obtain an antioxidation agent having strong antioxidation action and effective for the prevention and treatment of various diseases caused by oxidation. CONSTITUTION: This antioxidation agent contains torularhodin as an active component. Since torularhodin exhibits antioxidation action by capturing active oxygen, it is effective for preventing or suppressing the formation of lipid peroxide in the living body to prevent or suppress the injury of the oxidation reduction system in the living body. It is useful for the prevention and treatment of the damage caused by ischemia and reperfusion, myocardial infarction, stenocardia, retinitis, angitis, diabetes, dermatitis, crystalline lens opacification including cataract, pigmentation, etc. It is also useful as a stabilizing agent for foods, pharmaceuticals, cosmetics, etc., susceptible to oxidation. The administration dose of the agent for adult is 1-10mg/dose in terms of torularhodin and several doses per day.  In the case of using the agent as a stabilizer, it is compounded in an amount of 5×10&lt;-7&gt; to 1wt.% in terms of torularhodin based on the object to be stabilized.
PURPOSE:To provide an agent for suppressing hypertension by using Fomes japonicus as essential component. CONSTITUTION:Fomes japonicus (a fungus belonging to Polyporaceae family; Gododerma lucidum) is dried, crushed in the form of mince, frozen at &lt;=-10 deg.C, and crushed with a ball mill in frozen state. The crushed product is returned to normal temperature and sieved to collect the fraction between 10 mesh and 200 mesh. The fraction coarser than 10 mesh is frozen again, and crushed with a ball mill. The fraction having the above size is sterilized at low temperature to obtain an agent for hypertension. As an alternative method, Fomes japonicus is extracted with water or acetone. The powder or extract is formed in the form of powder, granule or tablet, optionally together with additives such as diluent, sweetener, excipient, etc.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a bathing agent so as to more effectively and simply practice a medicated bath, especially a foot bath by more persons and to provide bathing equipment for the foot bath.  &lt;P&gt;SOLUTION: A dried substance of a medicinal herb containing a medicinally effective component is housed in a water-permeable bag to provide the bathing agent. When the bathing agent is used as the foot bath, a pair of a left and a right heat insulating containers having a prescribed depth so that each human foot can be housed are used in combination. The body parts of the containers are connected so that the adjacent surfaces can be slid in the horizontal direction and a pair or a left and a right foot carrying plates with protrusions are housed in the bottoms of the container body parts. Rotators for assisting slide transfer are installed in an outer bottom or a lower part of the lateral part of the containers. Effective spots for applying moxa on the foot soles are strongly stimulated by the foot-carrying plates with the protrusions by performing slide movement. Since the medicated bath in the containers is stirred, the medicinally effective component is diffused to the whole medicated bath without settling in the container bottoms. Thereby, the medicinal effective component can uniformly be spread in bathing sites.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
The invention discloses a medical preparation for treatment of dog vomiting. The medical preparation is prepared by combination of pediatric theories of traditional Chinese medicine and veterinary theories of traditional Chinese medicine. The medical preparation comprises 1 bag of fattening baby pills, 4 terramycin tablets, and 20 to 30 cubic centimeters of liquor.&lt;{EN4}&gt;Most dogs will be cured by taking the medical preparation for two times.&lt;{EN5}&gt;The dosage above is designed for small dogs, and the dosage for large dogs is twice as much as the dosage for small dogs.&lt;{EN6}&gt;The dogs can not take meat or indigestible foods in 10 days after recovery. Most dogs will be cured by taking the medical preparation for two times. The dosage above is designed for small dogs, and the dosage for large dogs is twice as much as the dosage for small dogs. The dogs can not take meat or indigestible foods in 10 days after recovery.
FIELD: medicine, pharmaceutics. SUBSTANCE: a kit is suggested out of ready-to-use sterile form of hydrophilic ointment foundation and prostaglandins as active substance. Rheological parameters of ready-to-use product are proved experimentally corresponding to rheological optimum of extrusion capacity and are provided with foundation&#39;s composition. Individually dosed quantity of prostaglandins is proved with efficient dosage. Ointment foundation could be designed out of gels of sodium carboxymethylcellulose, random acrylic polymers (Arespol, Mars, etc.) or polyethylenoxides. Hermetically sealed reservoir could be represented by any packaging corresponding to purposes and bearing thermal sterilization with possibility for aseptic penetration into it. The preparation obtained is of high labor- stimulating activity at no side phenomena characteristic for prostaglandins, with possibility for individual dosage of active substance. EFFECT: higher efficiency of stimulation. 2 cl, 3 dwg, 1 tbl